Interview with the Innovators

Considerations for Selecting a First-Line Pancreatic Cancer Treatment

Videos
Tanios S. Bekaii-Saab, MD
David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ
Shubham Pant, MD
Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX
Michael Pishvaian, MD, PhD
Associate Professor of Oncology
Johns Hopkins University, Washington, DC

In this seventh installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations to keep in mind when selecting first-line treatment options such as FOLFIRINOX or NALIRIFOX for patients with pancreatic cancer.

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: